Bristol Myers Squibb account plan
Transforming patients' lives through science
At a glance
Bristol-Myers Squibb is a Princeton, NJ biopharmaceutical company with FY2025 revenues of $48,194 million and about 32,500 employees.
Bristol-Myers Squibb (BMS) discovers, develops, manufactures and sells medicines in oncology, hematology, immunology, cardiovascular and neuroscience, operating as a single segment. It sells mainly through wholesalers, distributors and specialty pharmacies; the United States made up 69% of FY2025 revenues and International 29%. FY2025 total revenues were $48,194 million (2024: $48,300 million), with net earnings attributable to BMS of $7,054 million. It had approximately 32,500 employees in 43 countries at December 31, 2025, and manufactures in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland.
Business units
Growth Portfolio
about 55% of FY2025 revenues ($26,409 million)Newer products early in their lifecycles, including Opdivo, Opdivo Qvantig, Yervoy, Opdualag, Reblozyl, Breyanzi, Camzyos, Orencia, Sotyktu and Cobenfy. Revenues grew 17% in FY2025 and 15% in Q2 2026 to $7,560 million. Adam Lenkowsky is EVP, Chief Commercialization Officer.
Legacy Portfolio
about 45% of FY2025 revenues ($21,785 million)Mature brands led by Eliquis (alliance with Pfizer, $14,443 million in FY2025), plus Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane, which face generic erosion. Revenues fell 15% in FY2025 and 4% in Q2 2026 to $5,422 million.
Strategic priorities
- Grow through the loss-of-exclusivity period
- Revlimid and Pomalyst face generics in the U.S., Eliquis EU patents expire in November 2026 and its U.S. LOE is April 2028; management still expects a $1.5 billion to $2 billion Eliquis step down in 2027.
- Launch the next wave of medicines
- Over 45 unique assets are in development; the CEO sees the potential for more than 10 new medicines by the end of the decade. Iberdomide (PDUFA August 17, 2026) and mezigdomide (PDUFA May 13, 2027) aim to replace Revlimid and Pomalyst in second line.
- AI across R&D and the enterprise
- BMS expanded its NVIDIA collaboration in July 2026 and agreed in May 2026 to deploy Claude from Anthropic across research, clinical development, manufacturing, commercial and corporate functions. The CEO believes AI can take two to three years off development.
- Strategic productivity initiative
- The initiative is expected to deliver annual cost savings of approximately $2.0 billion by the end of 2027.
- Disciplined capital allocation
- Business development remains a top allocation priority alongside debt reduction: net debt fell to $31,656 million at June 30, 2026 from $34,043 million at December 31, 2025.
Latest results
In Q2 2026 total revenues rose 6% to $12,973 million (H1 2026: $24,462 million, +4%). The Growth Portfolio grew 15% to $7,560 million, led by Opdivo Qvantig, Reblozyl, Camzyos and Breyanzi, while the Legacy Portfolio fell 4% as Eliquis (+22%) only partly offset Revlimid (-49%) and Pomalyst/Imnovid (-71%). GAAP EPS was $1.62 and non-GAAP EPS $2.04 (Q2 2025: $0.64 and $1.46). In July 2026 BMS raised 2026 revenue guidance to approximately $49.0 billion to $50.0 billion (from $46.0 billion to $47.5 billion) and non-GAAP EPS guidance to $6.75 - $7.00.
Investments and deals
- Hengrui collaboration
- May 2026 agreement on 13 early-stage assets in oncology, hematology and immunology: $600 million upfront and up to $14.3 billion of milestones plus royalties.
- 2025 deals
- Orbital Therapeutics acquisition (in vivo CAR-T), BioNTech collaboration on pumitamig ($1,500 million upfront) and a Philochem licence for a prostate cancer radiopharmaceutical.
- Manufacturing and R&D capex
- Capex of approximately $1.3 billion expected in 2026 for cell therapy and other manufacturing, R&D and additional U.S. domestic manufacturing; a new R&D facility in San Diego is planned for 2026.
- Divestment in China
- Sale of the 60% stake in Sino-American Shanghai Squibb Pharmaceuticals for $164 million of net cash proceeds and a $109 million gain.
Challenges and risks
- Generic erosion
- Revlimid licences are no longer volume-limited from January 31, 2026, Pomalyst has U.S. generics since March 2026, and Eliquis generics may launch in the U.S. in 2028.
- U.S. pricing pressure
- IRA maximum fair prices apply to Eliquis from January 1, 2026, Pomalyst from 2027 and Orencia from 2028; the December 2025 U.S. Government Agreement includes free Eliquis to Medicaid.
- Pipeline setbacks
- ODYSSEY-HCM missed its endpoints, the Cobenfy ARISE trial missed its primary endpoint, the milvexian ACS trial was stopped in November 2025 and its atrial fibrillation readout moved to Q1 2027.
- Declining royalties and debt
- Keytruda and Tecentriq royalties are expected to end on December 31, 2026, and the 10-K lists significant indebtedness among its risks.
- Access to patients
- Cobenfy access is limited because, per the CEO, half of U.S. counties lack a practicing psychiatrist.
What leadership says
“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business.”
“We certainly don't feel any compulsion to chase deals”
“Our goal is to make iber and mezi foundational in multiple myeloma, replacing Rev and Pom in second line over time.”
“We've already proven, for example, that you can take months off the time needed to write regulatory documents, using this technology.”
Where a supplier can help
- AI and data tooling for R&D
- Tied to the AI priority: BMS is putting AI across R&D and corporate functions, so suppliers of data, clinical trial optimisation or document automation tools fit the stated aim of shortening development.
- Launch readiness for new medicines
- Tied to the launch priority: iberdomide, mezigdomide and other filings create demand for commercial, medical and patient-access services, with SG&A rising for new product launches.
- Cost savings programmes
- Tied to the productivity initiative: a target of approximately $2.0 billion of savings by the end of 2027 favours suppliers who can show measurable cost reduction.
- Manufacturing and cell therapy capacity
- Tied to the approximately $1.3 billion 2026 capex for cell therapy, U.S. domestic manufacturing and the San Diego R&D facility.
- Patient access in underserved areas
- Tied to the access challenge: digital and outreach tools that reach patients without a local psychiatrist would support Cobenfy uptake.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Bristol Myers Squibb?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for the fiscal year ended December 31, 2025
- Bristol-Myers Squibb (Princeton, NJ) is a biopharmaceutical company operating in a single segment, focused on oncology, hematology, immunology, cardiovascular and neuroscience; it reports its products as a Growth Portfolio and a Legacy Portfolio. Approximately 32,500 employees in 43 countries at December 31, 2025, about 54% in the U.S.
- FY2025 total revenues of $48,194 million (2024: $48,300 million), relatively flat: the Growth Portfolio grew 17% to $26,409 million while the Legacy Portfolio fell 15% to $21,785 million. United States 69% of revenues, International 29%.
- GAAP diluted EPS of $3.46 (2024: loss of $4.41) and non-GAAP EPS of $6.15 (2024: $1.15); net earnings attributable to BMS $7,054 million, helped by much lower Acquired IPRD charges ($3,721 million vs $13,373 million in 2024, which included Karuna).
- Largest products: Eliquis $14,443 million (+8%), Opdivo $10,049 million (+8%), Orencia $3,705 million, Revlimid $2,951 million (-49%), Yervoy $2,900 million, Pomalyst/Imnovid $2,733 million, Reblozyl $2,327 million (+31%); fast growers Breyanzi (+82%), Camzyos (+77%), Krazati (+62%) and Cobenfy ($155 million).
- Loss of exclusivity is the core issue: generic Revlimid licenses are no longer volume-limited as of January 31, 2026, generic pomalidomide was expected in the U.S. in March 2026, Eliquis generics may launch in the U.S. in 2028 under settlements and EU patents/SPCs expire in November 2026; Opdivo's U.S. exclusivity date is 2028.
- Pricing pressure: IRA "maximum fair price" for Eliquis from January 1, 2026, Pomalyst from 2027, Orencia selected for 2028; a December 2025 U.S. Government Agreement gives Eliquis free to Medicaid and direct-to-patient discounts of approximately 80% on five brands in exchange for tariff relief until January 2029.
- Strategy: combine large-pharma scale with biotech speed; R&D priorities are science, execution and value, with AI infused across R&D. Pipeline of over 45 unique assets: pumitamig (BioNTech), CELMoDs iberdomide/mezigdomide/golcadomide, arlo-cel, radiopharmaceuticals (RayzeBio), admilparant, milvexian (with Johnson & Johnson), Cobenfy expansions.
- 2025 business development: Orbital Therapeutics acquisition, BioNTech collaboration ($1,500 million upfront), Philochem license; strategic productivity initiative expected to deliver approximately $2.0 billion of cost savings by the end of 2027.
- Balance sheet: net debt of $34,043 million (down $4.4 billion), operating cash flow $14,156 million, dividends $5.0 billion, capex approximately $1.3 billion expected in 2026; $8.7 billion of debt repurchased in late 2025.
- Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 total revenues $12,973 million, up 6% (H1: $24,462 million, +4%); U.S. $8,991 million (+6%), International $3,664 million (+5%).
- Growth Portfolio $7,560 million, up 15%; Legacy Portfolio $5,422 million, down 4%.
- Eliquis $4,481 million, up 22%, helped by a 2026 U.S. list price reduction that lowered rebates; Revlimid -49%, Pomalyst/Imnovid -71% (U.S. generics since March 2026).
- Growth drivers: Opdivo Qvantig $261 million (from $30 million), Reblozyl $735 million (+29%), Breyanzi $484 million (+41%), Camzyos $416 million (+60%), Opdualag $349 million (+23%), Cobenfy $63 million (+81%); Opdivo $2,485 million (-3%) as U.S. patients move to Qvantig.
- GAAP EPS $1.62 (Q2 2025: $0.64); non-GAAP EPS $2.04 ($1.46); net earnings attributable to BMS $3,317 million.
- GTN adjustments fell to 30% of gross sales (46% a year earlier) after the Eliquis list price cut.
- May 2026: global collaboration with Hengrui on 13 early-stage assets ($600 million upfront, up to $14.3 billion of milestones); sale of the 60% stake in Sino-American Shanghai Squibb ($109 million gain).
- Pipeline: iberdomide PDUFA August 17, 2026; mezigdomide May 13, 2027; Camzyos adolescents September 30, 2026; Reblozyl in MF-associated anemia March 11, 2027; Sotyktu PsA approved in the U.S. and EU; Opdivo approved in first-line cHL.
- Net debt reduced to $31,656 million; H1 operating cash flow $4,497 million, down on the Eliquis price reduction.
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 and Raises Full-Year Outlook
- Q2 2026 revenues of $13.0 billion, up 6% (+5% ex-FX); Growth Portfolio $7.6 billion, up 15% (+14% ex-FX), driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag.
- Legacy Portfolio $5.4 billion, down 4%: Eliquis demand growth was more than offset by generic impacts on the rest.
- GAAP EPS $1.62 and non-GAAP EPS $2.04 (Q2 2025: $0.64 and $1.46).
- 2026 guidance raised: revenues to approximately $49.0 billion to $50.0 billion (from $46.0 billion to $47.5 billion); non-GAAP EPS to $6.75 - $7.00 (from $6.05 - $6.35); operating expenses approximately $16.5 billion; gross margin approximately 69% - 70%; tax rate approximately 18%.
- Eliquis worldwide revenue growth guidance raised to 20% - 25% (from 10% - 15%).
- Non-GAAP gross margin 71.4% (72.6%), reflecting product mix; non-GAAP R&D $2.3 billion (+2%).
- Strategy: build a company delivering "industry-leading, sustainable growth into the 2030s and beyond"; AI partnerships with NVIDIA (Vera Rubin NVL72) and Anthropic (Claude across research, clinical, manufacturing, commercial and corporate functions); Hengrui deal on 13 early-stage programs.
- CEO Christopher Boerner: "The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents an expanding share of our overall business."
- Bristol Myers Squibb Q2 2026 earnings call transcript
- Q2 2026 call (July 30, 2026): CEO Christopher Boerner called it "another excellent quarter, driven by disciplined execution across the business"; Growth Portfolio up 14% (ex-FX) with 10 products growing double digits; 2026 revenue and EPS guidance raised.
- CFO David Elkins: Growth Portfolio $7.6 billion is "now representing nearly 60% of total revenue"; Qvantig "annualizing at over $1 billion" with 15% share, targeting 30% to 40%; Eliquis up 21% with growth guidance of 20% to 25%; legacy decline now 4% to 6%.
- Pivotal readouts expected by the end of 2026: admilparant (IPF), arlo-cel, iberdomide PFS, milvexian in secondary stroke prevention, RYZ101 in GEP-NETs and Sotyktu in lupus; milvexian atrial fibrillation readout moved to Q1 2027 and Cobenfy ADEPT readouts to early 2027.
- Boerner sees "the potential to introduce more than 10 new medicines by the end of the decade" plus "over 30 meaningful life cycle management opportunities".
- CELMoDs: Adam Lenkowsky said iberdomide and mezigdomide aim to replace Revlimid and Pomalyst "in second line over time"; 70% to 80% of myeloma patients are treated in the community.
- Eliquis LOE is April 2028 and should lead "directly into the successful launch of milvexian"; a $1.5 billion to $2 billion Eliquis step down is still expected in 2027.
- Business development "continues to be a top allocation priority" but BMS feels no "compulsion to chase deals"; AI partnerships with Anthropic and NVIDIA to understand biology, design molecules faster and decide earlier.
- Admilparant targets an IPF market of roughly $4 billion that could reach $8 billion to $10 billion by the mid-2030s, per Lenkowsky.
- Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his 'patent cliff' plan (Fortune)
- Fortune interview (December 5, 2025) with Chris Boerner, CEO and board chair, two years into the role, on the patent cliff facing Opdivo, Yervoy and Eliquis.
- His plan was modelled on how Lilly and AstraZeneca navigated loss-of-exclusivity periods; what he underestimated was culture: "how we keep everyone focused on executing against that".
- Washington: BMS decided three years ago "to staff up significantly" and changed almost its entire D.C. team to engage directly on policy.
- Pricing: prices must be equalised with industrialized countries that "can and should be paying more"; talks held in the U.K., with Germany and Japan next; Cobenfy to launch in the U.K. at the U.S. price.
- AI: BMS believes AI can take "two to three years" off development and raise Phase 3 success likelihood "to almost 100%"; it has already cut months from regulatory document writing.
- Access: Boerner wants BMS judged on patient benefit, not prescriptions; 50% of U.S. counties lack a practicing psychiatrist, which limits Cobenfy access.
- Ambition "to be a leader in brain health", with hopes for Alzheimer's and schizophrenia.
Questions about Bristol Myers Squibb
What does Bristol-Myers Squibb do?
BMS is a biopharmaceutical company that discovers, develops and sells medicines in oncology, hematology, immunology, cardiovascular and neuroscience. Its largest products include Eliquis and Opdivo.
What is Bristol-Myers Squibb's revenue?
FY2025 total revenues were $48,194 million. In July 2026 it guided 2026 revenues to approximately $49.0 billion to $50.0 billion.
How many employees does Bristol-Myers Squibb have?
Approximately 32,500 employees in 43 countries at December 31, 2025, about 54% in the U.S.
Who leads Bristol-Myers Squibb?
Christopher Boerner is Chair of the Board and Chief Executive Officer; David Elkins is EVP and CFO.
What is Bristol-Myers Squibb's strategy?
To grow the Growth Portfolio and launch new medicines through the Eliquis, Revlimid and Pomalyst losses of exclusivity, while cutting approximately $2.0 billion of costs by the end of 2027 and using AI across R&D.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)